Test Catalog

Test Id : LH

Luteinizing Hormone (LH), Serum

Useful For
Suggests clinical disorders or settings where the test may be helpful

An adjunct in the evaluation of menstrual irregularities


Evaluating patients with suspected hypogonadism


Predicting ovulation


Evaluating infertility


Diagnosing pituitary disorders

Method Name
A short description of the method used to perform the test

Electrochemiluminescence Immunoassay

NY State Available
Indicates the status of NY State approval and if the test is orderable for NY State clients.


Reporting Name
Lists a shorter or abbreviated version of the Published Name for a test

Luteinizing Hormone (LH), S

Lists additional common names for a test, as an aid in searching

Interstitial Cell Stimulating Hormone

Leuteotropic Hormone

Luteotropic Hormone

Pituitary gonadotropins

Luteinizing Hormone (LH)

Specimen Type
Describes the specimen type validated for testing


Ordering Guidance

1. The limit of quantitation for this test is 0.01 IU/L. In pediatric settings where greater analytical sensitivity is required, order LHPED / Luteinizing Hormone (LH), Pediatrics, Serum.

2. The preferred test to confirm menopausal status is FSH / Follicle-Stimulating Hormone (FSH), Serum.

Specimen Required
Defines the optimal specimen required to perform the test and the preferred volume to complete testing

Patient Preparation: For 12 hours before specimen collection do not take multivitamins or dietary supplements containing biotin (vitamin B7), which is commonly found in hair, skin, and nail supplements and multivitamins.

Collection Container/Tube:

Preferred: Serum gel

Acceptable: Red top

Submission Container/Tube: Plastic vial

Specimen Volume: 0.6 mL

Collection Instructions: Centrifuge and aliquot serum into a plastic vial within 2 hours of collection.


If not ordering electronically, complete, print, and send an Oncology Test Request (T729) with the specimen.

Specimen Minimum Volume
Defines the amount of sample necessary to provide a clinically relevant result as determined by the testing laboratory. The minimum volume is sufficient for one attempt at testing.

0.5 mL

Reject Due To
Identifies specimen types and conditions that may cause the specimen to be rejected

Gross hemolysis Reject
Gross lipemia OK

Specimen Stability Information
Provides a description of the temperatures required to transport a specimen to the performing laboratory, alternate acceptable temperatures are also included

Specimen Type Temperature Time Special Container
Serum Refrigerated (preferred) 7 days
Frozen 180 days
Ambient 24 hours

Useful For
Suggests clinical disorders or settings where the test may be helpful

An adjunct in the evaluation of menstrual irregularities


Evaluating patients with suspected hypogonadism


Predicting ovulation


Evaluating infertility


Diagnosing pituitary disorders

Clinical Information
Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test

Luteinizing hormone (LH) is a glycoprotein hormone consisting of 2 non-covalently bound subunits (alpha and beta). The alpha subunit of LH, follicle-stimulating hormone (FSH), thyrotropin (formerly known as thyroid-stimulating hormone: TSH), and human chorionic gonadotropin (hCG) are identical and contain 92 amino acids. The beta subunits of these hormones vary and confer the hormones' specificity. LH has a beta subunit of 121 amino acids and is responsible for interaction with the LH receptor. This beta subunit contains the same amino acids in sequence as the beta subunit of hCG, and both stimulate the same receptor; however, the hCG-beta subunit contains an additional 24 amino acids, and the hormones differ in the composition of their sugar moieties. Gonadotropin-releasing hormone from the hypothalamus controls the secretion of the gonadotropins, FSH, and LH, from the anterior pituitary.


In both males and females, LH is essential for reproduction. In females, the menstrual cycle is divided by a midcycle surge of both LH and FSH into a follicular phase and a luteal phase. This "LH surge" triggers ovulation thereby not only releasing the egg, but also initiating the conversion of the residual follicle into a corpus luteum that, in turn, produces progesterone to prepare the endometrium for a possible implantation. LH is necessary to maintain luteal function for the first 2 weeks. In case of pregnancy, luteal function will be further maintained by the action of hCG (a hormone very similar to LH) from the newly established pregnancy. LH supports thecal cells in the ovary that provide androgens and hormonal precursors for estradiol production. LH in males acts on testicular interstitial cells of Leydig to cause increased synthesis of testosterone.

Reference Values
Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.


< or =4 weeks: Not established

>1 month-< or =12 months: < or =0.4 IU/L

>12 months-< or =6 years: < or =1.3 IU/L

>6-< or =11 years: < or =1.4 IU/L

>11-< or =14 years: 0.1-7.8 IU/L

>14-< or =18 years: 1.3-9.8 IU/L

>18 years: 1.3-9.6 IU/L



< or =4 weeks: Not established

>1-< or =12 months: < or =0.4 IU/L

>12 months-< or =6 years: < or =0.5 IU/L

>6-< or =11 years: < or =3.1 IU/L

>11-< or =14 years: < or =11.9 IU/L

>14-< or =18 years: 0.5-41.7 IU/L



Follicular: 1.9-14.6 IU/L

Midcycle: 12.2-118.0 IU/L

Luteal: 0.7-12.9 IU/L

Postmenopausal: 5.3-65.4 IU/L

Provides information to assist in interpretation of the test results

In both males and females, primary hypogonadism results in an elevation of basal follicle-stimulating hormone (FSH) and luteinizing hormone (LH) levels.


Postmenopausal LH levels are generally above 40 IU/L.


FSH and LH are generally elevated in:

- Primary gonadal failure

- Complete testicular feminization syndrome

- Precocious puberty (either idiopathic or secondary to a central nervous system lesion)

- Menopause

- Primary ovarian hypodysfunction in females

- Polycystic ovary disease in females

- Primary hypogonadism in males


LH is decreased in:

- Primary ovarian hyperfunction in females

- Primary hypergonadism in males


FSH and LH are both decreased in failure of the pituitary or hypothalamus.

Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances

No clinically significant cross-reactivity has been demonstrated with follicle-stimulating hormone (FSH), thyrotropin (TSH), or human chorionic gonadotropin (hCG).


Some patients who have been exposed to animal antigens, either in the environment or as part of treatment or imaging procedures, may have circulating anti-animal antibodies present. These antibodies may interfere with the assay reagents to produce unreliable results.

Clinical Reference
Recommendations for in-depth reading of a clinical nature

1. Kaplan LA, Pesce AJ: The gonads. In: Kazmierczak SC, ed. Clinical Chemistry: Theory, Analysis, and Correlation. 3rd ed. Mosby-Year Book, Inc; 1996:894

2. Dumesic DA: Hyperandrogenic anovulation: a new view of polycystic ovary syndrome. Postgrad Ob Gyn. 1995;15:1-5

3. Rifai N, Horvath AR, Wittwer CT, eds: Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. 6th ed. Elsevier; 2018

Method Description
Describes how the test is performed and provides a method-specific reference

In the Roche luteinizing hormone (LH) assay, the determination of the LH level is made with the aid of a biotinylated monoclonal LH-specific antibody and a monoclonal LH-specific antibody labeled with a ruthenium complex, which form a sandwich complex. After addition of streptavidin-coated microparticles, the complex becomes bound to the solid phase via interaction of biotin and streptavidin. The reaction mixture is aspirated into the measuring cell where the microparticles are magnetically captured onto the surface of the electrode. Unbound substances are then removed with ProCell. Application of a voltage to the electrode then induces chemiluminescent emission that is measured by a photomultiplier.(Package insert: LH. Roche Diagnostics; 03/2019)

PDF Report
Indicates whether the report includes an additional document with charts, images or other enriched information


Day(s) Performed
Outlines the days the test is performed. This field reflects the day that the sample must be in the testing laboratory to begin the testing process and includes any specimen preparation and processing time before the test is performed. Some tests are listed as continuously performed, which means that assays are performed multiple times during the day.

Monday through Sunday

Report Available
The interval of time (receipt of sample at Mayo Clinic Laboratories to results available) taking into account standard setup days and weekends. The first day is the time that it typically takes for a result to be available. The last day is the time it might take, accounting for any necessary repeated testing.

Same day/1 to 3 days

Specimen Retention Time
Outlines the length of time after testing that a specimen is kept in the laboratory before it is discarded

7 days

Performing Laboratory Location
Indicates the location of the laboratory that performs the test


Several factors determine the fee charged to perform a test. Contact your U.S. or International Regional Manager for information about establishing a fee schedule or to learn more about resources to optimize test selection.

  • Authorized users can sign in to Test Prices for detailed fee information.
  • Clients without access to Test Prices can contact Customer Service 24 hours a day, seven days a week.
  • Prospective clients should contact their account representative. For assistance, contact Customer Service.

Test Classification
Provides information regarding the medical device classification for laboratory test kits and reagents. Tests may be classified as cleared or approved by the US Food and Drug Administration (FDA) and used per manufacturer instructions, or as products that do not undergo full FDA review and approval, and are then labeled as an Analyte Specific Reagent (ASR) product.

This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.

CPT Code Information
Provides guidance in determining the appropriate Current Procedural Terminology (CPT) code(s) information for each test or profile. The listed CPT codes reflect Mayo Clinic Laboratories interpretation of CPT coding requirements. It is the responsibility of each laboratory to determine correct CPT codes to use for billing.

CPT codes are provided by the performing laboratory.


LOINC® Information
Provides guidance in determining the Logical Observation Identifiers Names and Codes (LOINC) values for the order and results codes of this test. LOINC values are provided by the performing laboratory.

Test Id Test Order Name Order LOINC Value
LH Luteinizing Hormone (LH), S 10501-5
Result Id Test Result Name Result LOINC Value
Applies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure.
LH Luteinizing Hormone (LH), S 10501-5

Test Setup Resources

Setup Files
Test setup information contains test file definition details to support order and result interfacing between Mayo Clinic Laboratories and your Laboratory Information System.

Excel | Pdf

Sample Reports
Normal and Abnormal sample reports are provided as references for report appearance.

Normal Reports | Abnormal Reports

SI Sample Reports
International System (SI) of Unit reports are provided for a limited number of tests. These reports are intended for international account use and are only available through MayoLINK accounts that have been defined to receive them.

SI Normal Reports | SI Abnormal Reports